Dianthus Therapeutics (NASDAQ:DNTH) Earns “Buy” Rating from HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 44.51% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Oppenheimer increased their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday. Robert W. Baird initiated coverage on Dianthus Therapeutics in a research report on Friday, July 26th. They set an “outperform” rating and a $58.00 price objective on the stock. Raymond James raised their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Wedbush reduced their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $27.68 on Monday. The stock has a 50-day simple moving average of $27.73 and a 200 day simple moving average of $26.64. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The stock has a market capitalization of $812.96 million, a PE ratio of -11.07 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 22.37% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. As a group, equities research analysts forecast that Dianthus Therapeutics will post -2.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC raised its stake in shares of Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the last quarter. SG Americas Securities LLC bought a new position in Dianthus Therapeutics in the 2nd quarter valued at $112,000. The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics in the second quarter worth $236,000. WINTON GROUP Ltd bought a new stake in shares of Dianthus Therapeutics during the second quarter worth $265,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Dianthus Therapeutics in the second quarter valued at $334,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.